827031-26-5

Basic information

• Product Name: 4-[Methyl-(2-Methyl-quinazolin-4-yl)-aMino]-phenol
• Synonyms: 4-[Methyl-(2-Methyl-quinazolin-4-yl)-aMino]-phenol
• CAS NO: 827031-26-5
• Molecular Formula: C16H15N3O
• Molecular Weight: 265.3098
• Mol File: 827031-26-5.mol
• Article Data: 9

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 4-[Methyl-(2-Methyl-quinazolin-4-yl)-aMino]-phenol(CAS DataBase Reference)
• NIST Chemistry Reference: 4-[Methyl-(2-Methyl-quinazolin-4-yl)-aMino]-phenol(827031-26-5)
• EPA Substance Registry System: 4-[Methyl-(2-Methyl-quinazolin-4-yl)-aMino]-phenol(827031-26-5)

Safety Data

• Hazardous Substances Data: 827031-26-5(Hazardous Substances Data)

Upstream product

• 100-02-7 4-nitro-phenol 
• 880-03-5 4-(methoxymethoxy)-1-nitrobenzene 
• 876-30-2 4-methoxymethyloxyaniline 
• 86817-51-8 4-(methoxymethoxy)-N-methylaniline 
• 150-75-4 N-methyl-p-aminophenol 
• 6484-24-8 2-methyl-4-chloroquinazoline 
• 1769-24-0 4-hydroxy-2-methylquinazoline 
• 827031-83-4 N-(4-methoxyphenyl)-N,2-dimethyl-quinazolin-4-amine 

Relevant articles and documents

Radiosynthesis and in Vivo Evaluation of [11C]MPC-6827, the First Brain Penetrant Microtubule PET Ligand

Abnormalities of microtubules (MTs) are implicated in the pathogenesis of many CNS diseases. Despite the potential of an MT imaging agents, no PET ligand is currently available for in vivo imaging of MTs in the brain. We radiolabeled [11C]MPC-6

RADIOLABELED MICROTUBULE IMAGING COMPOUNDS AND USES THEREOF

The present disclosure relates to radiolabeled compounds and methods of uses for diagnosis, monitoring, and treatment of various degenerative neurological disorders, neuropsychiatric disorders, brain injuries, vascular diseases, and cancers. Radiolabeled compounds for imaging of microtubules or microtubules and other targets using positron-emission tomography (PET) are specifically disclosed.

A histone deacetylase inhibitor and its preparation and use (by machine translation)

The invention provides a compound of formula I illustrated compound or its pharmaceutically acceptable salt, relates to has the histone deacetylase inhibitory activity of the 4 - aryl amino [...] novel class of compound, the preparation of the compounds, comprising the pharmaceutical composition and the compounds and pharmaceutical compositions in the preparation of histone deacetylase enzyme inhibitor drug in its class of use; aimed at through the drug design and synthesis means based on obtaining a series of 4 - aryl amino [...] surface of the cleat and linkage area optimization, with subtype selective and good medicine generation of dynamics characteristic of selective histone deacetylase inhibitors, in order to improve the anti-tumor activity at the same time to reduce the impact of the normal tissue or cells. (by machine translation)